MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (Paris:ALTHE) (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, is pleased to announce the rapidly growing number of thyroid nodule treatments by Echopulse®, thus confirming the strong potential anticipated from this indication.
Initially focused on the development of treatment of breast fibroadenomas, Theraclion decided at the end of 2014 to enlarge its strategy to include the treatment of thyroid nodules. Since the start of 2015, seven sites have opened offering routine clinical treatment of thyroid nodules with the Echopulse system, six of those sites opened in the final months of the year.
A strong pole of activity has established in Germany: The Echolpulse is offered in nuclear medicine facilities in Paderborn, Bremen and Bottrop, as well as at the surgical department of Bürgerhospital in Frankfurt. With the first reimbursement agreements for the thyroid procedure obtained, coverage of the procedure is now available to nearly half a million individuals in Germany, providing a solid foundation from which Theraclion’s development strategy will continue to build. The average reimbursement by insurance providers is 2,200€, which will allow for a quick return on investment and a significant reduction of health costs compared to classic thyroid nodule treatment.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
An analysis of the performed thyroid treatment using Echopulse in routine clinical practice tripled in the past six months compared to the number of treatments performed prior to that date. The average number of patients treated in sites opened since the end of 2015 amounted to 3.5 per month and is expected to grow rapidly over the next months. All combined, more than 180 thyroid treatments (including clinical studies) were conducted with the Echopulse system.
David Caumartin, Theraclion’s CEO, says, “The significant rise in the number of thyroid treatments since the reinforcing of our strategy is excellent news. It confirms the interest of centers and patients for our technology. Moreover, the opening of new sites proves the profitability of outpatient treatments performed with or without local anesthesia.”
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.Back to HCB News